Vertex Pharmaceuticals: I'm Downgrading To Hold On Drug Pricing, Pipeline Concerns

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...

Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...
Game Rant on MSN

Boruto: Kishimoto Has Confirmed Boruto's Next Form, And It Could Make Him the Strongest

Thankfully, Kishimoto has already laid the groundwork for Boruto’s powerful new form in Two Blue Vortex. Jura is still ...

FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation

The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.
Zacks Investment Research on MSN

Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Zacks Investment Research on MSN

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $381.87, demonstrating a +1.39% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.5%. At ...